Company Overview
Company Type: Private Company
Website: www.halifaxbiomedical.com
Number of Employees: -
Year Founded: 2004
Total Amount Raised (CAD mm)†: 3.05
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Halifax Biomedical Inc., a biomedical company, engages in the delivery of contract research services; and development of diagnostic medical equipment. It offers clinical trails, including ankle arthroplasty, knee arthroplasty, fracture fixation, hip arthroplasty, bone cement, modular total knee replacement, spinal fusion devices, and modular total hip replacement; a proprietary computer program to simulate stereo X-rays; Halifax Roentgen stereophotogrammetric analysis bead inserters; tantalum bead sets; Halifax stereo radiography suite; dual-purpose and clinical/research imaging system solutions; direct digital imaging platform solutions; centralized data analysis and support solutions; integrated quality management solutions; and study management, study design, pre-study computer simulation, pre-study planning, surgeon training, stereo imaging training, system testing, image analysis, data management and quality control, and scientific reporting services. The company also offers aseptic loosening, spinal fusion, fracture healing, poly-wear, bone stiffness measure, joint kinematics, base literature, and current studies/clinical database services. Halifax Biomedical Inc. was founded in 2004 and is based in Mabou, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Munro, Chad
Founder, Chief Executive Officer, President and Director

Key Board Members
Name
Title
Snider, Carol 
Chairman
Munro, Chad
Founder, Chief Executive Officer, President and Director
Horton, David
Director
Orr, Robert 
Director
Schwartz, Irving
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
11493 Route 19 | Mabou, NS | B0E 1X0 | Canada
Phone: 902-945-2771   Fax: 902-945-2324

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Enterprise Cape Breton Corporation
Oct-28-2011
Minority
-
Growth
NSBI Venture Capital
Oct-28-2011
Minority
-
Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-28-2011
Dec-31-2011
Private Placement
Target
Halifax Biomedical Inc.
NSBI Venture Capital,Enterprise Cape Breton Corporation

3.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-27-2014
Client Announcements
Halifax Biomedical Enters into Distribution Agreement with Signature Orthopaedics
Dec-31-2011
Private Placements
Halifax Biomedical Inc. announced that it has received $3 million in funding from Enterprise Cape Breton Corporation and NSBI Venture Capital.
Oct-28-2011
Private Placements
Halifax Biomedical Inc. announced that it expects to receive $3 million in funding from Enterprise Cape Breton Corporation and NSBI Venture Capital.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 25, 2023 01:15 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Jun 23, 2023 12:22 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Mar 23, 2023 09:38 PM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Dec 21, 2022 02:37 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Sep 24, 2022 07:04 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Jun 23, 2022 11:37 PM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Mar 24, 2022 01:56 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
19
GlobalData

Dec 20, 2021 06:53 AM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
15
GlobalData

Sep 22, 2021 08:48 PM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
10
GlobalData

Jun 17, 2021 12:11 PM
Halifax Biomedical Inc.
Halifax Biomedical Inc
Reports
10


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Snider, Carol 
Chairman
902-945-2771
902-945-2324

Munro, Chad
Founder, Chief Executive Officer, President and Director
902-945-2771
902-945-2324
-
Horton, David
Director
902-945-2771
902-945-2324
-
Orr, Robert 
Director
902-945-2771
902-945-2324
-
Schwartz, Irving
Director
902-945-2771
902-945-2324
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Munro, Chad
Founder, Chief Executive Officer, President and Director
902-945-2771
902-945-2324
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
